Patents Examined by Karen E. Brown
  • Patent number: 5821084
    Abstract: A previously undiscovered transmembrane protein tyrosine phosphatase expressed only in bone and testis, osteotesticular protein tyrosine phosphatase (OST-PTP), has been identified, cloned, sequenced, expressed and subjected to enzymatic analysis. Also, a truncated osteoblast specific form (OST) containing the OST-PTP receptor but lacking the catalytic domain was identified and characterized. Based on the unique expression pattern of OST-PTP and OST during osteogenesis, assays can be used to screen for abnormal bone growth patterns and metabolic bone diseases. Moreover, this novel protein provides a specific target for use in conventional and gene therapies directed at treatment of osteoporosis, osteopetrosis and other bone metabolic disorders.
    Type: Grant
    Filed: November 21, 1994
    Date of Patent: October 13, 1998
    Assignees: The Regents of the University of Michigan, American Home Products Corporation
    Inventors: Elizabeth Ann Olmsted, Laura Jeanne Mauro, Alan Robert Davis, Jack Edward Dixon
  • Patent number: 5817511
    Abstract: The present invention relates to new nucleotide sequences coding for variable regions of the .alpha. chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: October 6, 1998
    Assignee: Roussel Uclaf
    Inventors: Thierry Hercend, Frederic Triebel, Sergio Roman-Roman, Laurent Ferradini
  • Patent number: 5811517
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Patent number: 5811518
    Abstract: The invention provides substantially purified T-cadherin polypeptides and isolated nucleic acids which encode the T-cadherin polypeptides. Antibodies reactive with various forms of T-cadherin, but not reactive with N-, E- or P-cadherin are also provided. The invention provides methods for detecting the various forms of T-cadherin in a subject as well as a method of detecting tumor growth which consists of inhibiting the activity of T-cadherin in a tumor. A method of affecting traumatized neurons is provided. The method entails treating traumatized neurons with a therapeutically effective dose of T-cadherin.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: La Jolla Cancer Research Foundation
    Inventor: Barbara Ranscht
  • Patent number: 5780426
    Abstract: The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 14, 1998
    Assignee: IXSYS, Incorporated
    Inventors: Michael A. Palladino, Bruce A. Lee, William D. Huse, Judith A. Varner
  • Patent number: 5780263
    Abstract: A human Small CCN-Like Growth Factor polypeptide (SCGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonist against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in SCGF nucleic acid sequences and altered levels of the SCGF polypeptide are also disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 14, 1998
    Assignee: Human Genome Sciences, Inc.
    Inventors: Gregg A. Hastings, Mark D. Adams
  • Patent number: 5773218
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 30, 1998
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Patent number: 5770686
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated "ICAM-R") and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Patent number: 5767077
    Abstract: Soluble and membrane-bound forms of human FC.gamma.RIII are provided, together with nucleic acids capable of encoding the same. Soluble Fc.gamma.RIIIs are useful in ameliorating the serum platelet deficiency associated with immune thrombocytopenic purpura. Cells expressing membrane-bound Fc.gamma.RIIIs are useful components in assays for serum immune complexes.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 16, 1998
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gary A. Peltz, Kevin W. Moore
  • Patent number: 5753502
    Abstract: DNA sequences, derived from the 5' region of the human neuron-specific cellular adhesion molecule ICAM-4, which promote neuron-specific gene transcription are disclosed along with polynucleotides comprising the promoter DNA operatively linked to heterologous gene-encoding polynucleotides, expression vectors comprising the promoter DNA, and host cells transformed or transfected with DNA comprising the promoter sequences.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: May 19, 1998
    Assignee: ICOS Corporation
    Inventors: Patrick D. Kilgannon, W. Michael Gallatin
  • Patent number: 5750502
    Abstract: This invention provides an isolated vertebrate nucleic acid molecule encoding F-spondin. This invention also provides a probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding an F-spondin. This invention further provides a method of attaching nerve cells to a matrix comprising contacting the matrix with nerve cells and purified F-spondin at a concentration effective to effect attachment of the cells to the matrix. This invention also provides a method of stimulating growth of a nerve cell comprising contacting the nerve cell with purified F-spondin at a concentration effective to stimulate growth of the nerve cell. This invention provides a method of regenerating nerve cells in a subject comprising administering to the subject purified F-spondin at a concentration effective to regenerate nerve cells in the subject.
    Type: Grant
    Filed: January 5, 1995
    Date of Patent: May 12, 1998
    Assignee: The Trustees of Columbia University in City of New York
    Inventors: Thomas M. Jessell, Avihu Klar
  • Patent number: 5747280
    Abstract: A human Vascular IBP-Like Growth Factor polypeptide (VIGF) and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for wound healing or tissue regeneration, stimulating implant fixation and angiogenesis. Antagonists against such polypeptides and their use as a therapeutic to treat atherosclerosis, tumors and scarring are also disclosed. Diagnostic assays for identifying mutations in VIGF nucleic acid sequences and altered levels of the VIGF polypeptide are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 5, 1998
    Assignee: Human Genome Sciences, Inc.
    Inventors: Gregg A. Hastings, Craig A. Rosen
  • Patent number: 5736400
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: April 7, 1998
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Patent number: 5726037
    Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
  • Patent number: 5726290
    Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
  • Patent number: 5726152
    Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: March 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Marvin L. Bayne, Gregory L. Conn, Kenneth A. Thomas, Jr.
  • Patent number: 5723583
    Abstract: Disclosed is a method of inhibiting the binding of a cell bearing a cell adhesion protein to a molecule or cell bearing a carbohydrate determinant specific for the cell adhesion molecule. The method involves contacting the cell adhesion protein-bearing cell with an inhibitor molecule bearing the carbohydrate determinant. Also disclosed is a method of inhibiting the binding of the first member of a specific binding pair to the second member of the specific binding pair, involving contacting the first member with an antibody which is specific for the first member and which is covalently bonded to a carbohydrate moiety which interferes with the antibody's ability to fix complement and bind an F.sub.c receptor. The methods of the invention may be used, for example, to reduce inflammation.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 3, 1998
    Assignee: The General Hospital Corporation
    Inventors: Brian Seed, Gerd Walz
  • Patent number: 5719127
    Abstract: Analogs of regulators of complement activation (RCA) proteins which have altered specificities and affinities for the targets C3b and/or C4b are described. These analogs are obtained by substituting amino acids which effect the binding of these proteins, identified as amino acids 35, 64-65, 92-94 (C4b) and the sequence S-T-K-P-(P-I-C)-Q (C3b) in the CR1 protein can be transferred to corresponding regions of CR1 or of additional members of the RCA family. Analogs can also be designed by substituting amino acids which affect the binding of these proteins into homologous regions of noncorresponding SCRs of CR1 or other family members.
    Type: Grant
    Filed: July 30, 1996
    Date of Patent: February 17, 1998
    Assignee: Washington University
    Inventors: John P. Atkinson, Dennis Hourcade, Malgorzata Krych
  • Patent number: 5719125
    Abstract: A novel human chondromodulin-I protein having a molecular weight of about 26,000 dalton on SDS-PAGE and capable of stimulating the growth of chondrocytes with or without FGF, promoting the differential potency of these cells, and inhibiting the growth of vascular endothelial cells, a DNA encoding this protein, expression vector containing the DNA, a transformant capable of producing recombinant chondromodulin-I protein, a process for producing chondromodulin-I protein by culturing the transformant and a pharmaceutical composition containing chondromodulin-I protein as an active ingredient.
    Type: Grant
    Filed: May 11, 1994
    Date of Patent: February 17, 1998
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Fujio Suzuki, Yuji Hiraki, Kazuhiro Takahashi, Junko Suzuki, Jun Kondo, Atsuko Kohara, Akiko Mori, Ei Yamada
  • Patent number: 5716789
    Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 10, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Johan Sundelin, Robert M. Scarborough